Early Phase Oncology: First-In-Human Study Of An Antibody-Drug Conjugate In Breast Cancer

Case study

For a First In Human study, site activation and enrollment can present challenges, but when you add in investigator differences in opinions and team turnover, things can quickly get chaotic.

This case study will show you efficiencies and advanced benefits gained by having the expert and proactive full-service team at Aixial Group by your side, helping to differentiate your trial from all others.

Phase I ADC Breast Cancer Case Study

Trial Summary

  • Accelerated-titration design followed by the standard “3+3” design
  • Escalation: solid tumor
  • Expansion: two pre-specified cohorts (TNBC and not TNBC)

Product: Intravenous administration
Sites: 3 escalation (USA), (7 expansion USA & Europe)
Dates: 2019 to present
Services: Full Service

Successes

  • Rapid site activation, ahead of schedule
  • Enrollment ahead of schedule in escalation
  • Cooperative engagement with sites during single enrollment slot availability
  • Prompt dose escalation review and decisions by smart data entry support and easy data visibility using encapsia insights/patient profiles
  • No DTLs and single SAE (to date) quickly handled with electronic reporting processes and advanced data visibility via encapsia

Figure 1. Real-time enrollment insight(s) support cohort management

Figure 2. Real-time, customizable results over time insights facilitate on-safety oversight

Challenges with Mitigations

  • Multiple physicians supporting this trial have led to differences i opinion.
  • Aixial established clear communication pathways to address and resolve differences quickly, to not impede enrollment, medical oversight, safety management, etc.
  • Internal sponsor team turnover resulted in rework, but the Aixial team was able to support and resolve this quickly
  • Aixial project manager turnover (n=1) addressed with senior oversight by stepping into the project to apply their historical knowledge of the project to ease the transition burden on site and sponsor teams

Reach out to us at info@aixial.com

Other insightful resources

A phase II basket trial of (IP) in combination with (drug) in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations

A phase II basket trial of (IP) in combination with (drug) in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations

Pancreatic cancer is the 12th most common cancer in the world and remains one of the deadliest, with a five-year survival rate of only 13%, despite recent progress.

A Phase II Open -Label Safety and Efficacy Study of combination IP in patients with progressed advanced malignancies

A Phase II Open -Label Safety and Efficacy Study of combination IP in patients with progressed advanced malignancies

Did you know that lung cancer is the most diagnosed cancer in the world? In 2022, it accounted for 12.4% of all new cancer cases and 18.7% of deaths. The 5-year survival rate for lung cancer has increased by 22% over the last 5 years due to advances in treatment. However, only 26% of cases are diagnosed at an early stage, when the survival rate is 61%.

Safety, Preliminary Efficacy and Pharmacokinetics of [IP] in Metastatic Castrate Resistant Prostate Cancer

Safety, Preliminary Efficacy and Pharmacokinetics of [IP] in Metastatic Castrate Resistant Prostate Cancer

Prostate cancer is on the increase globally, especially in men under the age of 50, and in 2022 there were 1.47 million new cases. The 5-year survival rate is close to 100%, largely thanks to advances in treatment and early detection.